{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T18:57:20Z","timestamp":1760122640170},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"S1","license":[{"start":{"date-parts":[[2017,2,23]],"date-time":"2017-02-23T00:00:00Z","timestamp":1487808000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Res Cardiol Suppl"],"published-print":{"date-parts":[[2017,3]]},"DOI":"10.1007\/s11789-017-0090-3","type":"journal-article","created":{"date-parts":[[2017,2,23]],"date-time":"2017-02-23T05:36:09Z","timestamp":1487828169000},"page":"22-26","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Primary and secondary prevention of cardiovascular disease in patients with hyperlipoproteinemia\u00a0(a)"],"prefix":"10.1007","volume":"12","author":[{"given":"P.","family":"Gr\u00fctzmacher","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B.","family":"\u00d6hm","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Szymczak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Dorbath","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Brzoska","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Kleinert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,2,23]]},"reference":[{"key":"90_CR1","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1001\/jama.1993.03510180065035","volume":"270","author":"P Ridker","year":"1993","unstructured":"Ridker P, Hennekens C, Stampfer M (1993) A prospective study of lipoprotein(a) and the risk of myocardial infarction. JAMA 270:2195\u20132199","journal-title":"JAMA"},{"key":"90_CR2","first-page":"412","volume":"303","author":"Emerging Risk Factors Collaboration","year":"2009","unstructured":"Emerging Risk Factors Collaboration (2009) Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality. JAMA 303:412\u2013423","journal-title":"JAMA"},{"key":"90_CR3","doi-asserted-by":"crossref","first-page":"2844","DOI":"10.1093\/eurheartj\/ehq386","volume":"31","author":"B Nordestgaard","year":"2010","unstructured":"Nordestgaard B, Chapman M, Ray K et\u00a0al (2010) Lipoprotein(a) as a\u00a0cardiovascular risk factor: current status. Eur Heart\u00a0J 31:2844\u20132853","journal-title":"Eur Heart J"},{"key":"90_CR4","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.1056\/NEJMoa1600177","volume":"374","author":"S Yusuf","year":"2016","unstructured":"Yusuf S, Lonn E, Pais P et al (2016) Blood-pressure and cholesterol lowering in persons without cardiovascular disease. N\u00a0Engl J Med 374:2032\u20132043","journal-title":"N Engl J Med"},{"key":"90_CR5","doi-asserted-by":"crossref","first-page":"2021","DOI":"10.1056\/NEJMoa1600176","volume":"374","author":"S Yusuf","year":"2016","unstructured":"Yusuf S, Bosch J, Dagenais G et al (2016) Cholesterol lowering in intermediate-risk persons without cardiovascular disease. N\u00a0Engl J Med 374:2021\u20132031","journal-title":"N Engl J Med"},{"key":"90_CR6","doi-asserted-by":"publisher","first-page":"2999","DOI":"10.1093\/eurheartj\/ehw272","volume":"37","author":"A Catapano","year":"2016","unstructured":"Catapano A, Graham I, De Backer G et\u00a0al (2016) ESC\/EAS, guidelines for the management of dyslipidaemias. Eur Heart\u00a0J 37:2999\u20133058. doi: 10.1093\/eurheartj\/ehw272","journal-title":"Eur Heart J"},{"key":"90_CR7","doi-asserted-by":"crossref","first-page":"3268","DOI":"10.1093\/eurheartj\/eht053","volume":"34","author":"KM Kostner","year":"2013","unstructured":"Kostner KM, M\u00e4rz W, Kostner GM (2013) When should we measure lipoprotein(a)? Eur Heart\u00a0J 34:3268\u20133270","journal-title":"Eur Heart J"},{"key":"90_CR8","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1111\/j.1365-2796.2012.02592.x","volume":"273","author":"F Kronenberg","year":"2013","unstructured":"Kronenberg F, Utermann G (2013) Lipoprotein(a) resurrected by genetics. J\u00a0Intern Med 273:6\u201330","journal-title":"J Intern Med"},{"key":"90_CR9","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1111\/j.1523-1755.2004.00737.x","volume":"66","author":"F Kronenberg","year":"2004","unstructured":"Kronenberg F, Lingenhel A, Lhotta K et al (2004) Lipoprotein(a) and low density-derived cholesterol in nephrotic syndrome. Kidney Int 66:348\u2013394","journal-title":"Kidney Int"},{"key":"90_CR10","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1194\/jlr.R061648","volume":"57","author":"SM Marcovina","year":"2016","unstructured":"Marcovina SM, Albers JJ (2016) Lipoprotein (a) measurement for clinical application. J\u00a0Lipid Res 57:526\u2013537","journal-title":"J Lipid Res"},{"key":"90_CR11","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/S0140-6736(12)61731-0","volume":"381","author":"M Cuchel","year":"2013","unstructured":"Cuchel M, Meagher EA, du Toit TH et\u00a0al (2013) Efficacy and safety of a\u00a0microsomal triglyceride transfer protein inhibitor. Lancet 381:40\u201346","journal-title":"Lancet"},{"key":"90_CR12","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1111\/j.1365-2125.2012.04469.x","volume":"76","author":"ST Crooke","year":"2013","unstructured":"Crooke ST, Geary RS (2013) Clinical pharmacological properties of mipomersen (Kynamro),a second generation antisense inhibitor of apolipoprotein B. Br J Clin Pharmacol 76:269\u2013276. doi: 10.1111\/j.1365-2125.2012.04469.x","journal-title":"Br J Clin Pharmacol"},{"key":"90_CR13","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1161\/atvbaha.114.304549","volume":"35","author":"R Santos","year":"2015","unstructured":"Santos R, Raal F, Catapano A et\u00a0al (2015) Mipomersen, an antisense oligonucleotide to apolipoprotein B100, reduces lipoprotein(a) in various populations with hypercholesterolemia. Arterioscler Thromb Vasc Biol 35:689\u2013699. doi: 10.1161\/atvbaha.114.304549","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"90_CR14","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1161\/CIRCULATIONAHA.113.001969","volume":"128","author":"N Desai","year":"2013","unstructured":"Desai N, Kohili P, Giugliano R et\u00a0al (2013) AMG145, a\u00a0monoclonal antibody against PCSK9, significantly reduces lipoprotein(a) in hypercholesterolemic patients receiving statin therapy. Circulation 128:962\u2013969","journal-title":"Circulation"},{"key":"90_CR15","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.amjcard.2016.09.010","volume":"119","author":"D Gaudet","year":"2017","unstructured":"Gaudet D, Gerald F, Watts et\u00a0al (2017) Effect of alirocumab on lipoprotein(a) over \u22651.5 Years. Am J Cardiol 119:40\u201346. doi: 10.1016\/j.amjcard.2016.09.010","journal-title":"Am J Cardiol"},{"key":"90_CR16","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1016\/S0140-6736(15)61252-1","volume":"386","author":"S Tsimikas","year":"2015","unstructured":"Tsimikas S, Viney NJ, Hughes SG et al (2015) Antisense therapy targeting apolipoprotein (a): a\u00a0randomized, doubleblind placebo-controlled phase I study. Lancet 386:1472\u20131483","journal-title":"Lancet"},{"key":"90_CR17","first-page":"1","volume":"B7","author":"Bundesausschuss der \u00c4rzte und Krankenkassen","year":"2013","unstructured":"Bundesausschuss der \u00c4rzte und Krankenkassen (2013) Richtlinie zu Untersuchungs- und Behandlungsmethoden der vertrags\u00e4rztlichen Versorgung (MVV-RL) Durchf\u00fchrung der Apheresen als extrakorporales H\u00e4motherapieverfahren. BAnz AT B7:1\u20133 (08.04.2013)","journal-title":"BAnz AT"},{"key":"90_CR18","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1038\/ncpcardio1456","volume":"6","author":"BR Jaeger","year":"2009","unstructured":"Jaeger BR, Richter Y, Nagel D et\u00a0al (2009) Longitudinal cohort study on the effectiveness of lipid apheresis treatment to reduce high lipoprotein(a) levels and prevent major adverse coronary events. Nat Clin Pract Cardiovasc Med 6:229\u2013239","journal-title":"Nat Clin Pract Cardiovasc Med"},{"key":"90_CR19","doi-asserted-by":"crossref","first-page":"2567","DOI":"10.1161\/CIRCULATIONAHA.113.002432","volume":"128","author":"J Leebmann","year":"2013","unstructured":"For the Pro(a)Life-study group, Leebmann J, R\u00f6seler E, Julius U et al (2013) Lipoprotein apheresis in patients with maximally tolerated lipid lowering therapy, Lp(a)-hyperlipoproteinemia and progressive cardiovascular disease \u2013 a\u00a0prospective observational multicenter study. Circulation 128:2567\u20132567","journal-title":"Circulation"},{"key":"90_CR20","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1111\/aor.12135","volume":"38","author":"A Rosada","year":"2014","unstructured":"Rosada A, Kassner U, Vogt A et\u00a0al (2014) Does regular lipid apheresis in patients with isolated elevated lipoprotein(a) levels reduce the incidence of cardiovascular events? Artif Organs 38:135\u2013141","journal-title":"Artif Organs"},{"key":"90_CR21","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.atherosclerosissup.2012.10.005","volume":"14","author":"M Dryander Von","year":"2013","unstructured":"Von Dryander M, Fischer S, Passauer J et\u00a0al (2013) Differences in the atherogenic risk of patients treated by lipoprotein apheresis according to their lipid pattern. Atheroscler Suppl 14:39\u201344","journal-title":"Atheroscler Suppl"},{"key":"90_CR22","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.atherosclerosissup.2015.02.013","volume":"18","author":"F Heigl","year":"2015","unstructured":"Heigl F, Hettich R, Lotz N et al (2015) Efficacy, safety and tolerability of long-term lipoprotein apheresis in patients with LDL- or Lp (a)-hyperlipoproteinamia. Atheroscler Suppl 18:154\u2013163","journal-title":"Atheroscler Suppl"},{"key":"90_CR23","doi-asserted-by":"crossref","first-page":"2019","DOI":"10.1161\/ATVBAHA.116.307983","volume":"36","author":"E Roeseler","year":"2016","unstructured":"Roeseler E, Julius U, Heigl F et al (2016) Lipoprotein apheresis for lipoprotein(a)-associated cardiovascular disease: prospective 5 years of follow-up and apolipoprotein(a) characterization. Arterioscler Thromb Vasc Biol 36:2019\u20132202","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"90_CR24","volume-title":"KBV-Qualit\u00e4tsbericht Ausgabe 2015 Berichtsjahr 2014","author":"Kassen\u00e4rztliche Bundesvereinigung","year":"2016","unstructured":"Kassen\u00e4rztliche Bundesvereinigung (2016) KBV-Qualit\u00e4tsbericht Ausgabe 2015 Berichtsjahr 2014. www.kbv.de\/media\/sp\/KBV_Qualitaetsbericht_2014.pdf"},{"key":"90_CR25","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1161\/ATVBAHA.107.145805","volume":"27","author":"S Kiechl","year":"2007","unstructured":"Kiechl S, Willeit J, Mayr M et al (2007) Oxydised phospholipids,lipoprotein(a),lipoprotein-associated phospholipase A2 activity and 10-year cardiovascular outcome. Prospective results from the Bruneck study. Arterioscler Thromb Vasc Biol 27:1788\u20131795","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"90_CR26","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1161\/CIRCULATIONAHA.107.715698","volume":"117","author":"P Kamstrup","year":"2008","unstructured":"Kamstrup P, Benn M, Tybaerg-Hansen A et al (2008) Extreme lipoprotein(a) levels and risk of myocardial inforation in the general population. The Copenhagen City Heart study. Circulation 117:176\u2013184","journal-title":"Circulation"},{"key":"90_CR27","doi-asserted-by":"crossref","first-page":"2518","DOI":"10.1056\/NEJMoa0902604","volume":"361","author":"R Clarke","year":"2009","unstructured":"Clarke R, Peden JF, Hopewell JC et\u00a0al (2009) Procardis consortium. Genetic variants associated with Lp(a) level and coronary heart disease. N\u00a0Engl J Med 361:2518\u20132528","journal-title":"N Engl J Med"},{"key":"90_CR28","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1111\/j.1365-2362.1994.tb02373.x","volume":"24","author":"P Cremer","year":"1994","unstructured":"Cremer P, Nagel D, Labrot B (1994) Lipoprotein(a) as a\u00a0predictor of myocardial infarction in comparison to fibrinogen, LDL cholesterol and other risk factors. Results of the Goettingen Incidence and prevalence study (Grips). Eur J Clin Invest 24:444\u2013453","journal-title":"Eur J Clin Invest"},{"key":"90_CR29","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1016\/S0735-1097(00)01126-8","volume":"37","author":"A Eckardstein Von","year":"2001","unstructured":"Von Eckardstein A, Schulte H, Cullen P, Assmann G (2001) Lipoprotein (a) further increases the risk of coronary events in men with high cardiovascular risk. J\u00a0Am Coll Cardiol 37:434\u2013439","journal-title":"J Am Coll Cardiol"},{"key":"90_CR30","isbn-type":"print","volume-title":"Schwere Dyslipoprotein\u00e4mie-Strategien zu Diagnostik und Therapie","author":"K Parhofer","year":"2007","unstructured":"Parhofer K (2007) Schwere Dyslipoprotein\u00e4mie-Strategien zu Diagnostik und Therapie. UniMed, Bremen. ISBN 978-3895992322","ISBN":"http:\/\/id.crossref.org\/isbn\/9783895992322"},{"key":"90_CR31","first-page":"216","volume-title":"Handbuch der Fettstoffwechselst\u00f6rungen","author":"H Kraft","year":"2007","unstructured":"Kraft H, Utermann A (2007) Lipoprotein(a). In: Schwandt P, Parhofer K (eds) Handbuch der Fettstoffwechselst\u00f6rungen. Schattauer, Stuttgart, pp\u00a0216\u2013230"},{"key":"90_CR32","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1097\/00004872-200018060-00008","volume":"18","author":"LA Sechi","year":"2000","unstructured":"Sechi LA, Catena C, Casaccio D, Zigaro L (2000) Lipoprotein (a) haemostatic variables and cardiocascular damage in hypertensive patients. J\u00a0Hypertens 18:709\u2013716","journal-title":"J Hypertens"},{"key":"90_CR33","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/S0140-6736(02)09358-3","volume":"360","author":"S Yussuf","year":"2002","unstructured":"Yussuf S (2002) Commentary: two decades of progress in preventing cardiovascular disease. Lancet 360:2\u20133","journal-title":"Lancet"},{"key":"90_CR34","doi-asserted-by":"crossref","first-page":"e669","DOI":"10.1378\/chest.11-2307","volume":"141","author":"P Alonso-Coello","year":"2012","unstructured":"Alonso-Coello P, Bellmunt S, McGrorian C et al (2012) Antithrombotic therapy in peripheral artery disease: Antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 141:e669\u2013e690","journal-title":"Chest"},{"key":"90_CR35","unstructured":"S3 Leitlinie _Teil\u00a01:Sekund\u00e4rprophylaxe isch\u00e4mischer Schlaganfall und transitorische isch\u00e4mische Attacke online www.dyn.org\/images\/red_leitlinien\/LL-2014\/pdf-Download\/030-133_kurz-S3-Sekund\u00e4rprophylaxe_isch\u00e4mischer_Schlaganfall_2015-02.pdf"},{"key":"90_CR36","doi-asserted-by":"publisher","first-page":"2315","DOI":"10.1093\/eurheartj\/ehw106","volume":"37","author":"M Piepoli","year":"2016","unstructured":"Piepoli M, Hoes A, Agewall S et\u00a0al (2016) European Guidelines on cardiovascular disease prevention in clinical practice. Eur Heart\u00a0J 37:2315\u20132381. doi: 10.1093\/eurheartj\/ehw106","journal-title":"Eur Heart J"},{"key":"90_CR37","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1186\/s12916-015-0358-8","volume":"13","author":"XL Zhang","year":"2015","unstructured":"Zhang XL, Zhu QQ, Zhu L et al (2015) Safety and efficacy of anti-PCSK9 antibodies: a\u00a0meta-analysis of 25 randomized, controlled trials. BMC Med 13:123","journal-title":"BMC Med"},{"key":"90_CR38","doi-asserted-by":"crossref","first-page":"2423","DOI":"10.1056\/NEJMoa1611594","volume":"375","author":"C Gibson","year":"2016","unstructured":"Gibson C, Mehran R, Bode C et\u00a0al (2016) Prevention of bleeding in patients with atrial fibrillation undergoing PCl. N\u00a0Engl J Med 375:2423\u20132435","journal-title":"N Engl J Med"},{"key":"90_CR39","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1097\/00043798-199604000-00014","volume":"3","author":"JE Hokanson","year":"1996","unstructured":"Hokanson JE, Austin MA (1996) Plasma triglyceride level is a\u00a0risk factor independent of high density cholesterol. A meta-analysis of population-based prospective studies. J\u00a0Cardiovasc Risk 3:213\u2013219","journal-title":"J Cardiovasc Risk"},{"key":"90_CR40","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1055\/s-0032-1330232","volume":"21","author":"T Wayne","year":"2012","unstructured":"Wayne T (2012) A review of the role of anticoagulation in the treatment of peripheral arterial disease. Int J Angiol 21:187\u2013189","journal-title":"Int J Angiol"}],"container-title":["Clinical Research in Cardiology Supplements"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11789-017-0090-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11789-017-0090-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11789-017-0090-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,6,25]],"date-time":"2017-06-25T07:11:56Z","timestamp":1498374716000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11789-017-0090-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,2,23]]},"references-count":40,"journal-issue":{"issue":"S1","published-print":{"date-parts":[[2017,3]]}},"alternative-id":["90"],"URL":"https:\/\/doi.org\/10.1007\/s11789-017-0090-3","relation":{},"ISSN":["1861-0706","1861-0714"],"issn-type":[{"value":"1861-0706","type":"print"},{"value":"1861-0714","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,2,23]]}}}